PMCB (PharmaCyte Biotech) Change In Working Capital: $-1.93 Mil (TTM As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PMCB PharmaCyte Biotech Inc PMCB
33 GF Score
Price $0.49
! 2 Warning Signs
View Full Analysis

What is PharmaCyte Biotech Change In Working Capital?

PharmaCyte Biotech PMCB +0.53% 33 Change In Working Capital is $-1.93 Mil as of Apr. 2026. GuruFocus rates PMCB with a GF Score™ of 33/100. The stock has 2 warning signs investors should review.

PharmaCyte Biotech's change in working capital for the quarter that ended in Apr. 2026 was $-1.08 Mil.

PharmaCyte Biotech's change in working capital for the fiscal year that ended in Apr. 2026 was $-1.93 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

PharmaCyte Biotech Change In Working Capital Related Terms

PharmaCyte Biotech Change In Working Capital Historical Data

* Premium members only.

The historical data trend for PharmaCyte Biotech's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCyte Biotech Change In Working Capital Chart

PharmaCyte Biotech Annual Data
Trend Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25 Apr26
Change In Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 -0.30 0.30 1.36 -1.93

PharmaCyte Biotech Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Change In Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.26 -0.96 0.13 -0.02 -1.08
PMCB
33GF Score
PharmaCyte Biotech Inc PMCB
Change In Working Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaCyte Biotech Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.93 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows Fiscal Years EndedJanuary 31,(Amounts in millions)
Cash flows from operating activities: 2014 2013 2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net (566) (614) (796)
Inventories (1,667) (2,759) (3,727)
Accounts payable 531 1,061 2,687
Accrued liabilities 103 271 (935)
Accrued income taxes (1,224) 981 994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Change In Working Capital of $-1.93 Mil mean?
PharmaCyte Biotech (PMCB) has a Change In Working Capital of $-1.93 Mil as of Apr. 2026. Change in Working Capital is the difference between current assets less current liabilities between the current period and the past period. View historical data for PharmaCyte Biotech.
Is PharmaCyte Biotech's Change In Working Capital too high?
PharmaCyte Biotech's current Change In Working Capital is $-1.93 Mil. Overall, PharmaCyte Biotech has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's Change In Working Capital compare to JUNS and PULM?
PharmaCyte Biotech's Change In Working Capital of $-1.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Working Capital for a Biotechnology company?
A good Change In Working Capital depends on the Biotechnology industry context. However, Change In Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Working Capital mean?
A high Change In Working Capital can signal that a stock is expensive relative to its fundamentals. Change in Working Capital is the difference between current assets less current liabilities between the current period and the past period. View historical data for PharmaCyte Biotech. PharmaCyte Biotech's current Change In Working Capital is $-1.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current Change In Working Capital of $-1.93 Mil. The current Change In Working Capital is $-1.93 Mil. PharmaCyte Biotech's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Working Capital calculated?
Change In Working Capital is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current Change In Working Capital is $-1.93 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCyte Biotech Business Description

Address 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
33GF Score

Get the complete analysis for PMCB

Change In Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.49
Price